Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group
| Autor: | F. Del Gaizo, S. Mancarella, Antonio Farris, S. Palmeri, Annunziato Iannelli, G. De Cataldis, Salvatore Tafuto, Pasquale Comella, L. De Lucia, E. Crucitta, F. De Vita, F. Buzzi, Luigi Maiorino |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Leucovorin Neutropenia Adenocarcinoma Irinotecan Gastroenterology Disease-Free Survival Drug Administration Schedule Folinic acid Bolus (medicine) Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Aged Neoplasm Staging Chemotherapy Dose-Response Relationship Drug business.industry Biopsy Needle Remission Induction Hematology Middle Aged medicine.disease Prognosis Survival Analysis Surgery Regimen Methotrexate Treatment Outcome Oncology Italy Fluorouracil Camptothecin Female business Colorectal Neoplasms medicine.drug |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 13(6) |
| ISSN: | 0923-7534 |
| Popis: | Purpose: The purpose of this study was to compare the activity and toxicity of the combination of irinotecan (IRI) plus folinic acid (FA)-modulated 5-fluorouracil (5-FU) i.v. bolus with a regimen of double modulation of 5-FU with methotrexate (MTX) and FA in patients with advanced colorectal carcinoma. Patients and methods: Two-hundred and thirty-four patients were enrolled: 118 patients received IRI 200 mg/m 2 (90-min i.v. infusion) on day 1, followed by levo-FA 250 mg/m 2 (2-h i.v. infusion) and 5-FU 850 mg/m 2 (i.v. bolus) on day 2(IRIFAFU), and 116 patients received MTX 750 mg/m 2 (2-h i.v. infusion) on day 1, followed by levo-FA 250 mg/m 2 (2-h i.v. infusion) and FU 800 mg/m 2 (i.v. bolus) on day 2 (MTXFAFU). Both cycles were repeated every 2 weeks until progression or to a maximum of 16 cycle. Response rate (RR) was the main end point of the study; responses were assessed every four cycles and confirmed after 2 additional months of treatment. Results: RR was significantly greater with IRIFAFU (36%) than with MTXFAFU (20%) (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|